On January 11, 2016, Cheryl Moore joined the New York Genome Center as President and Chief Operating Officer. A highly esteemed and nationally recognized research executive, Moore will assume responsibility for all business functions of the NYGC, reporting to and partnering with Robert B. Darnell, MD, PhD, to set overall strategic direction and make key business decisions for the organization.
“We are very excited to be adding another exceptional individual to the management team of the Genome Center,” said Dr. Darnell. “Our ability to recruit Cheryl demonstrates the importance and potential of the work we are doing in the rapidly evolving field of genomic research.”
Previously Moore was the Executive Vice President and Chief Operating Officer of the Howard Hughes Medical Institute where she led collaborative strategic efforts and oversaw key operational functions. She held this position for five years. From 2004 until 2010, Moore served as Chief Operating Officer of HHMI’s Janelia Research Campus, where she played a pivotal role in Janelia’s startup and was responsible for all operational aspects of the campus and its $100 million budget. Prior to joining HHMI, she served as Senior Vice President and Chief Operating Officer of the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California.
“The Genome Center sits at the forefront of scientific innovation, and I’m honored to join the organization,” said Ms. Moore. “It’s an exciting time to be developing the power of genomics in New York, hand-in-hand with our founding members, collaborators and supporters. I look forward to working with the scientific and operational team at the Genome Center to advance this promising technology in support of human health.”
Moore is a graduate of the University of San Diego and has prior work experience in public accounting/startup consulting and worked with early stage companies engaged in the biotech, technology, and healthcare services industries.
About the New York Genome Center
The New York Genome Center (NYGC) is an independent, nonprofit at the forefront of transforming biomedical research and clinical care with the mission of saving lives. As a consortium of renowned academic, medical and industry leaders across the globe, NYGC focuses on translating genomic research into clinical solutions for serious disease. Our member organizations and partners are united in this unprecedented collaboration of technology, science, and medicine. We harness the power of innovation and discoveries to improve people’s lives — ethically, equitably, and urgently. Member institutions include: Albert Einstein College of Medicine, American Museum of Natural History, Cold Spring Harbor Laboratory, Columbia University, Cornell University/Weill Cornell Medicine, Hospital for Special Surgery, The Jackson Laboratory, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, NewYork-Presbyterian Hospital, The New York Stem Cell Foundation, New York University, Northwell Health (formerly North Shore-LIJ), The Rockefeller University, Roswell Park Cancer Institute, Stony Brook University and IBM.
